The stock has a 36-month beta value of 0.51. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for EWTX is 73.99M, and at present, short sellers hold a 14.04% of that float. On April 15, 2025, the average trading volume of EWTX was 1.74M shares.
EWTX) stock’s latest price update
Edgewise Therapeutics Inc (NASDAQ: EWTX)’s stock price has plunge by 8.43relation to previous closing price of 12.33. Nevertheless, the company has seen a 16.36% surge in its stock price over the last five trading sessions. 247wallst.com reported 2025-04-08 that Market volatility has spiked since the beginning of April, due largely to uncertainty about inflation, interest rates, upcoming quarterly reports, and mostly the impact of tariffs and a global trade war on the U.S.
EWTX’s Market Performance
Edgewise Therapeutics Inc (EWTX) has seen a 16.36% rise in stock performance for the week, with a -49.42% decline in the past month and a -51.42% plunge in the past quarter. The volatility ratio for the week is 11.26%, and the volatility levels for the past 30 days are at 11.47% for EWTX. The simple moving average for the past 20 days is -24.55% for EWTX’s stock, with a -47.03% simple moving average for the past 200 days.
Analysts’ Opinion of EWTX
Many brokerage firms have already submitted their reports for EWTX stocks, with Scotiabank repeating the rating for EWTX by listing it as a “Sector Perform.” The predicted price for EWTX in the upcoming period, according to Scotiabank is $14 based on the research report published on April 02, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see EWTX reach a price target of $50. The rating they have provided for EWTX stocks is “Sector Outperform” according to the report published on March 07th, 2025.
Stifel gave a rating of “Hold” to EWTX, setting the target price at $30 in the report published on January 22nd of the current year.
EWTX Trading at -41.92% from the 50-Day Moving Average
After a stumble in the market that brought EWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.93% of loss for the given period.
Volatility was left at 11.47%, however, over the last 30 days, the volatility rate increased by 11.26%, as shares sank -49.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.54% lower at present.
During the last 5 trading sessions, EWTX rose by +16.49%, which changed the moving average for the period of 200-days by -23.51% in comparison to the 20-day moving average, which settled at $17.72. In addition, Edgewise Therapeutics Inc saw -49.93% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EWTX starting from Thompson Peter A., who purchase 496,771 shares at the price of $20.13 back on Apr 03 ’25. After this action, Thompson Peter A. now owns 14,809,075 shares of Edgewise Therapeutics Inc, valued at $10,000,000 using the latest closing price.
ORBIMED ADVISORS LLC, the Director of Edgewise Therapeutics Inc, purchase 496,771 shares at $20.13 during a trade that took place back on Apr 03 ’25, which means that ORBIMED ADVISORS LLC is holding 14,809,075 shares at $10,000,000 based on the most recent closing price.
Stock Fundamentals for EWTX
The total capital return value is set at -0.34. Equity return is now at value -34.40, with -32.37 for asset returns.
Based on Edgewise Therapeutics Inc (EWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -23.02.
Currently, EBITDA for the company is -158.83 million with net debt to EBITDA at 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.93.
Conclusion
To sum up, Edgewise Therapeutics Inc (EWTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
